XML 114 R42.htm IDEA: XBRL DOCUMENT v3.22.4
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Kite Pharma, Inc. (Details)
$ in Thousands
1 Months Ended
Sep. 30, 2019
USD ($)
material_right
performance_obligation
Apr. 30, 2018
USD ($)
option
milestone
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Accounts receivable     $ 3,678 $ 6,013
Kite Pharma, Inc. | License and Service        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Contract with customer liability   $ 150,000    
Number of remaining performance obligations | performance_obligation 4      
Number of material rights for renewal of research period | material_right 2      
Renewal period 1 year      
Fixed consideration $ 150,000      
Remaining performance obligation amount     19,700 51,400
Kite Pharma, Inc. | Collaboration and license agreement        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Milestone payments received   $ 150,000    
Initial research term of agreement   6 years    
Number of options to extend initial research term | option   2    
Extended research term of agreement   1 year    
Separate fee for additional term   $ 10,000    
Contract with customer liability     19,400 56,500
Accounts receivable     $ 700 $ 100
Kite Pharma, Inc. | Collaboration and license agreement | Achievement of specified research, clinical development, regulatory and first commercial sale milestones        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Contingent development and sales-based milestone payments to be received   1,300,000    
Kite Pharma, Inc. | Collaboration and license agreement | Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Contingent development and sales-based milestone payments to be received   $ 1,800,000    
Maximum amount of achieved milestones to receive payment | milestone   10    
Kite Pharma, Inc. | Collaboration and license agreement | Maximum        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Development and sales-based milestone payments to be received   $ 3,000,000